Phathom Pharmaceuticals is a high-risk pharmaceutical company based in the United States. Specializing in the development of novel treatments for GI diseases, the company's main product, vonoprazan, is an ESG medicine that blocks acid secretion in the stomach. With rapid and potent anti-secretory effects, vonoprazan has shown clinical benefits for conditions like GERD and H. pylori infection. ESG-score: 33.8.